Publications by authors named "Christopher Assaid"

Claim this Profile
M
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Angélica Jayk Bernal, Monica M Gomes da Silva, Dany B Musungaie, Evgeniy Kovalchuk, Antonio Gonzalez, Christopher Assaid

N Engl J Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.
José R Arribas, Sanjay Bhagani, Suzana M Lobo, Ilsiyar Khaertynova, Lourdes Mateu, Christopher Assaid

NEJM Evid· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.
Yoseph Caraco, Gordon E Crofoot, Pablo Andres Moncada, Anna Nikolaevna Galustyan, Dany Badibanga Musungaie, Christopher A Assaid

NEJM Evid· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
David R Muccino, Alyn H Morice, Surinder S Birring, Peter V Dicpinigaitis, Ian D Pavord, Christopher Assaid

ERJ Open Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
W Joseph Herring, Christopher Assaid, Kerry Budd, Ryan Vargo, Ralph S Mazenko

Clin Neuropharmacol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of hypersensitivity and anaphylaxis with sugammadex.
K Chris Min, Tiffany Woo, Christopher Assaid, Jacqueline McCrea, Deborah M Gurner

J Clin Anesth· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease.
Tiffini Voss, Jerry Li, Jeffrey Cummings, Martin Farlow, Christopher Assaid

Alzheimers Dement (N Y)· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant.
W Joseph Herring, Joy Y Ge, Saheeda Jackson, Christopher Assaid, Kathryn M Connor

Clin J Pain· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
William Joseph Herring, Tiffany Woo, Christopher A Assaid, Robert J Lupinacci, Hendrikus J Lemmens

J Clin Anesth· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Neuromuscular Blockade Improves Laparoscopic Surgical Conditions: A Randomized, Controlled Study.
Jacob Rosenberg, W Joseph Herring, Manfred Blobner, Jan P Mulier, Niels Rahe-Meyer, Christopher A Assaid

Adv Ther· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
Tiffini Voss, Richard B Lipton, David W Dodick, Nicole Dupre, Joy Yang Ge, Christopher Assaid

Cephalalgia· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine.
Tony W Ho, Andrew P Ho, Yang Joy Ge, Christopher Assaid, Regina Gottwald

Cephalalgia· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs.
David J Hewitt, Eric Pearlman, Mirja Hämäläinen, Donald Lewis, Kathryn M Connor, Christopher Assaid

Headache· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.
Tony W Ho, Eric Pearlman, Donald Lewis, Mirja Hämäläinen, Kathryn Connor, Christopher Assaid

Cephalalgia· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine.
David J Hewitt, Sheena K Aurora, David W Dodick, Peter J Goadsby, Yang Joy Ge, Christopher Assaid

Cephalalgia· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.
David W Dodick, James Kost, Christopher Assaid, Christopher Lines, Tony W Ho

Cephalalgia· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
Tony W Ho, Michel D Ferrari, David W Dodick, Vince Galet, James Kost, Christopher Assaid

Lancet· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial.
Paul S Aisen, Leon J Thal, Steven H Ferris, Christopher Assaid, Michael L Nessly

Curr Alzheimer Res· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years.
Elyssa Z Ott, Monte D Mills, Santiago Arango, Albert J Getson, Christopher A Assaid

Arch Ophthalmol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
Leon J Thal, Steven H Ferris, Louis Kirby, Gilbert A Block, Christopher R Lines, Christopher Assaid

Neuropsychopharmacology· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
James W Hainer, Donald J Sherrard, Suzanne K Swan, Jeffrey S Barrett, Christopher A Assaid

Am J Kidney Dis· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.
James W Hainer, Jeffrey S Barrett, Christopher A Assaid, Michael J Fossler, Donna S Cox

Thromb Haemost· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis